Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 10

1.

Bioavailability, Biotransformation, and Excretion of the Covalent Bruton Tyrosine Kinase Inhibitor Acalabrutinib in Rats, Dogs, and Humans.

Podoll T, Pearson PG, Evarts J, Ingallinera T, Bibikova E, Sun H, Gohdes M, Cardinal K, Sanghvi M, Slatter JG.

Drug Metab Dispos. 2019 Feb;47(2):145-154. doi: 10.1124/dmd.118.084459. Epub 2018 Nov 15.

PMID:
30442651
2.

Validation and reproducibility of an LC-MS/MS method for emixustat and its three deaminated metabolites in human plasma.

Podoll T, Geisler L, Parys MV, Hanson G, Reid MJ.

Bioanalysis. 2018 Oct 16. doi: 10.4155/bio-2018-0159. [Epub ahead of print]

PMID:
30325202
3.

First-in-human phase 1 of YS110, a monoclonal antibody directed against CD26 in advanced CD26-expressing cancers.

Angevin E, Isambert N, Trillet-Lenoir V, You B, Alexandre J, Zalcman G, Vielh P, Farace F, Valleix F, Podoll T, Kuramochi Y, Miyashita I, Hosono O, Dang NH, Ohnuma K, Yamada T, Kaneko Y, Morimoto C.

Br J Cancer. 2017 Apr 25;116(9):1126-1134. doi: 10.1038/bjc.2017.62. Epub 2017 Mar 14.

4.

Bioanalysis of emixustat (ACU-4429) in whole blood collected with volumetric absorptive microsampling by LC-MS/MS.

Miao Z, Farnham JG, Hanson G, Podoll T, Reid MJ.

Bioanalysis. 2015;7(16):2071-83. doi: 10.4155/bio.15.125.

PMID:
26327186
5.

Structure based design of an in vivo active hydroxamic acid inhibitor of P. aeruginosa LpxC.

Warmus JS, Quinn CL, Taylor C, Murphy ST, Johnson TA, Limberakis C, Ortwine D, Bronstein J, Pagano P, Knafels JD, Lightle S, Mochalkin I, Brideau R, Podoll T.

Bioorg Med Chem Lett. 2012 Apr 1;22(7):2536-43. doi: 10.1016/j.bmcl.2012.01.140. Epub 2012 Feb 16.

PMID:
22401863
6.

In vitro metabolism of clindamycin in human liver and intestinal microsomes.

Wynalda MA, Hutzler JM, Koets MD, Podoll T, Wienkers LC.

Drug Metab Dispos. 2003 Jul;31(7):878-87.

PMID:
12814964
7.

Catalytic role of cytochrome P4503A4 in multiple pathways of alfentanil metabolism.

Labroo RB, Thummel KE, Kunze KL, Podoll T, Trager WF, Kharasch ED.

Drug Metab Dispos. 1995 Apr;23(4):490-6.

PMID:
7600917
8.

Use of midazolam as a human cytochrome P450 3A probe: II. Characterization of inter- and intraindividual hepatic CYP3A variability after liver transplantation.

Thummel KE, Shen DD, Podoll TD, Kunze KL, Trager WF, Bacchi CE, Marsh CL, McVicar JP, Barr DM, Perkins JD, et al.

J Pharmacol Exp Ther. 1994 Oct;271(1):557-66.

PMID:
7965756
9.

Use of midazolam as a human cytochrome P450 3A probe: I. In vitro-in vivo correlations in liver transplant patients.

Thummel KE, Shen DD, Podoll TD, Kunze KL, Trager WF, Hartwell PS, Raisys VA, Marsh CL, McVicar JP, Barr DM, et al.

J Pharmacol Exp Ther. 1994 Oct;271(1):549-56.

PMID:
7965755
10.

Human liver microsomal enflurane defluorination catalyzed by cytochrome P-450 2E1.

Thummel KE, Kharasch ED, Podoll T, Kunze K.

Drug Metab Dispos. 1993 Mar-Apr;21(2):350-7.

PMID:
8097708

Supplemental Content

Loading ...
Support Center